Results 251 to 260 of about 30,272 (291)

Erratum: Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 <i>in vitro</i> and <i>in vivo</i> in NB xenografts. [PDF]

Mol Ther Oncol
Chu Y, Nayyar G, Tian M, Lee DA, Ozkaynak MF, Ayala-Cuesta J, Klose K, Foley K, Mendelowitz AS, Luo W, Liao Y, Ayello J, Behbehani GK, Riddell S, Cripe TP, Cairo MS.   +15 more
europepmc   +1 more source

Narrative Horizons: Deliberate Derangement in Oceanic Climate Fiction

Future Humanities, Volume 4, Issue 1, May 2026.
ABSTRACT Although we live in the Anthropocene—the geological age of humankind, wherein humans have measurably impacted the biosphere—we struggle to narrate the Anthropocene. In particular, we struggle to give narrative shape to its foremost feature: anthropogenic climate change.
Mark Celeste
wiley   +1 more source

In vivo CAR therapies: Turning the patient into their own CAR factory

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Over the past decade, ex vivo autologous chimeric antigen receptor (CAR)‐T‐cell therapies have reshaped the treatment of B‐cell malignancies. Despite their remarkable clinical efficacy, their application remains limited by complex manufacturing processes, demanding logistics, long turnaround times, and substantial costs. In vivo CAR approaches
François Vilcot, Carole‐Anne Brugère, Jaime Fuentealba, Roch Houot   +3 more
wiley   +1 more source

Nanobody-Based CAR NK Cells for Possible Immunotherapy of Mesothelin⁺ Tumors. [PDF]

Immune Netw
Jung D, Choi E, Jeoung YH, Lee J, Gong EY, Jo SG, Noh K, Ha K, Wee G, Kim H, Jung J, Kim S.   +11 more
europepmc   +1 more source

Donor-derived CD19-targeted CAR-NK cells induce complete remission in a child with relapsed B-ALL after failure of blinatumomab and autologous CD19-targeted CAR-T. [PDF]

J Immunother Cancer
Wang N, Liu L, Zhang L, Li J, Wan Y, Li X, Chen X, Yin Z, Zhang A, Zhang X, Chen Y, Hu T, Zhang Y, Liu F, Zhu X, Yang W.   +15 more
europepmc   +1 more source

CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy. [PDF]

Front Immunol
Dos Reis FD, Saidani Y, Martín-Rubio P, Sanz-Pamplona R, Stojanovic A, Correia MP.   +5 more
europepmc   +1 more source

Chimeric antigen receptor natural killer (CAR-NK) cells: from preclinical promise to clinical reality in cancer immunotherapy. [PDF]

Immunotherapy
Cochran HC, Ghobadi KA, Ghobadi A.
europepmc   +1 more source

Engineering Innate Immunity: Recent Advances and Future Directions for CAR-NK and CAR-Macrophage Therapies in Solid Tumors. [PDF]

Cancers (Basel)
Amoozgar B, Bangolo A, Mansour C, Elias D, Mohamed A, Thor DC, Ehsanullah SU, Tran HH, Aguilar IK, Weissman S.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

CAR-NK cells: a promising cellular immunotherapy in lymphoma

Expert Opinion on Biological Therapy, 2022
New methods in cancer immunotherapy, such as chimeric antigen receptor (CAR)-T cells, have shown promising results in destroying malignant cells. However, limitations and side effects of CAR-T cell therapy, such as graft-versus-host disease (GVHD), neurotoxicity, and cytokine release syndrome, have motivated researchers to investigate safer alternative
Shaghayegh, Khanmohammadi, Nima, Rezaei
openaire   +2 more sources

CAR-NK-Zellen im Einsatz der Immunonkologie

Trillium Immunologie, 2020
Die adoptive Immuntherapie ist ein vielversprechender Ansatz im Kampf gegen Krebs. Nach dem großen Erfolg und ersten Erfahrungen mit der Verwendung von CAR (chimärer Antigen-Rezeptor)-T-Zellen stehen weitere Immunzellen im Fokus der Wissenschaft. NK-Zellen sind durch ihr angeborenes Potenzial zur Vernichtung von Tumorzellen sowie virusinfizierten ...
Andrea Quaiser, Lubomir Arseniev, Ulrike Koehl   +2 more
openaire   +1 more source